Stevanato Group: debut on the New York Stock Exchange

Stevanato Group celebrates initial public offering and first day of public trading on New York Stock Exchange (NYSE)

Stevanato Group S.p.A. (the “Company”) celebrates its debut on the New York Stock Exchange under the ticker symbol “STVN.” Founded by Giovanni Stevanato in 1949, the Company is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

“It is an honour for Stevanato Group to join the New York Stock Exchange and begin the next chapter in our storied history,” said Franco Stevanato, Executive Chairman of the Board of Directors of Stevanato Group. “The needs of our customers have always been a driving force behind our decision making in the markets we serve. Listing is the logical next step for our company and will enable us to further strengthen our integrated offering, increase market penetration across our business segments and accelerate growth. I am proud of what we have achieved and excited for our future as a listed company.”

“This is a very exciting time for Stevanato Group,” commented Franco Moro, Chief Executive Officer of Stevanato Group. “Our top priority remains driving continuous innovation through our unique engineering services to produce the highest quality drug containment and drug delivery solutions, to help simplify healthcare for patients worldwide.”

Moro continued, “As a listed company, we intend to continue to build on our leadership position within the drug development and delivery value chain through further investment in research and development and the expansion of our global footprint and capabilities.”

The Stevanato Group leadership team will commemorate the Company’s listing by ringing the NYSE Opening Bell on Tuesday July 20th, 2021.